MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.numecd.2019.12.005

Медицинская библиотека · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2019

Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.

van Eyk Huub J, Paiman Elisabeth H M, Bizino Maurice B, IJzermans Suzanne L, Kleiburg Fleur, Boers Tim G W, Rappel Eline J, Burakiewicz Jedrzej, Kan Hermien E, Smit Johannes W A, Lamb Hildo J, Jazet Ingrid M, Rensen Patrick C N

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Several studies have shown that glucagon-like peptide-1 (GLP-1) analogues can affect resting energy expenditure, and preclinical studies suggest that they may activate brown adipose tissue (BAT). The aim of the present study was to investigate the effect of treatment with liraglutide on energy metabolism and BAT fat fraction in patients with type 2 diabetes.

METHODS AND

RESULTS

In a 26-week double-blind, placebo-controlled trial, 50 patients with type 2 diabetes were randomized to treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after treatment for 4, 12 and 26 weeks, we assessed resting energy expenditure (REE) by indirect calorimetry. Furthermore, at baseline and after 26 weeks, we determined the fat fraction in the supraclavicular BAT depot using chemical-shift water-fat MRI at 3T. Liraglutide reduced REE after 4 weeks, which persisted after 12 weeks and tended to be present after 26 weeks (week 26 vs baseline: liraglutide -52 ± 128 kcal/day; P = 0.071, placebo +44 ± 144 kcal/day; P = 0.153, between group P = 0.057). Treatment with liraglutide for 26 weeks did not decrease the fat fraction in supraclavicular BAT (-0.4 ± 1.7%; P = 0.447) compared to placebo (-0.4 ± 1.4%; P = 0.420; between group P = 0.911).

CONCLUSION

Treatment with liraglutide decreases REE in the first 12 weeks and tends to decrease this after 26 weeks without affecting the fat fraction in the supraclavicular BAT depot. These findings suggest reduction in energy intake rather than an increase in REE to contribute to the liraglutide-induced weight loss.

TRIAL REGISTRY NUMBER: NCT01761318.

Для цитирования: van Eyk Huub J, Paiman Elisabeth H M, Bizino Maurice B, IJzermans Suzanne L, Kleiburg Fleur, Boers Tim G W, Rappel Eline J, Burakiewicz Jedrzej, Kan Hermien E, Smit Johannes W A, Lamb Hildo J, Jazet Ingrid M, Rensen Patrick C N. Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2019. DOI: 10.1016/j.numecd.2019.12.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.